UnitedHealth Group shares surged more than 11% in Friday trading, on track for their strongest single-day performance since 2009, after a regulatory filing revealed Warren Buffett’s Berkshire Hathaway had quietly built a $1.6 billion position in the health-insurance giant.
The conglomerate disclosed ownership of 5 million shares at the end of the second quarter, having sought regulatory permission to accumulate the stake in secret beginning late last year to avoid triggering a price spike.
The rally comes as a welcome reprieve for UnitedHealth, whose shares had more than halved in value over the past 12 months amid a series of sharp selloffs.
Until last week, the stock was trading near its 52-week low of $234.60.
Berkshire’s UNH purchase comes amid mounting headwinds
Berkshire’s purchase stands in contrast to mounting concerns about the company’s fundamentals.
UnitedHealth has been battered by rising reimbursement costs that have rippled across the healthcare sector, with its insurance division taking a particularly heavy hit.
The company’s public image also suffered after the December 2024 killing of UnitedHealthcare executive Brian Thompson, an event that drew attention to frustrations with the US health insurance system.
Adding to the turbulence, the Department of Justice is investigating the company for potential criminal Medicare fraud, following a Wall Street Journal report.
UnitedHealth confirmed in July it is complying with both criminal and civil requests.
The political climate has also turned more challenging.
Both the Trump administration and large pharmaceutical companies have targeted pharmacy-benefit managers, such as UnitedHealth’s Optum Rx, with proposals to cut them out of the drug pricing chain.
Valuation still rich despite price slide
Even after the steep decline, UnitedHealth shares are not trading at a discount.
The stock’s forward price-to-earnings ratio of 16.45 times is well above the industry average of 12.12.
Analyst sentiment has cooled rapidly, with five downward revisions to 2025 and 2026 earnings estimates over the past week alone.
The Zacks Consensus now points to a 36.4% drop in 2025 earnings per share, though revenues are expected to grow by more than 12% year-over-year.
The company’s removal from the Russell Top 200 Growth, Russell 1000 Growth, and Russell 3000 Growth indices underscores the shift in how investors view the stock—from a dependable growth name to a company struggling with cost inflation and margin compression.
Operational and regulatory pressures intensify
UnitedHealth’s challenges are not limited to earnings misses.
Rising volumes of high-acuity care, deteriorating Medicare Advantage economics, and higher medical loss ratios are weighing on profitability.
Molina Healthcare and Centene face similar cost headwinds, but UnitedHealth’s size has made it a high-profile target for regulators.
The DOJ probe into Medicare billing practices could bring fines or clawbacks.
Meanwhile, lawmakers are increasing scrutiny on PBMs, with proposals that could upend Optum Rx’s business model.
The potential regulatory shifts present a risk to long-term earnings visibility.
Management changes and long-term initiatives
In an effort to steady operations, UnitedHealth has appointed Wayne DeVeydt—who recently stepped down from Centene’s board—as chief financial officer.
The company hopes fresh leadership will help navigate its operational and reputational challenges.
Management has outlined plans to leverage artificial intelligence and digital platforms to streamline costs and improve efficiency.
Its UnitedHealthcare division reported serving 50.1 million members as of June 30, 2025, a 2.1% increase from a year earlier, driven by growth in self-funded commercial plans.
Broader industry trends, including an aging population and rising chronic disease prevalence, continue to support long-term demand for healthcare services.
Dividend growth signals confidence
Despite the challenges, UnitedHealth returned $4.5 billion to shareholders in the second quarter through dividends and buybacks.
In June, the company raised its quarterly dividend by 5%, a move seen as a signal of confidence in its long-term cash flow.
The company has also indicated that Medicare Advantage rate increases in 2026 could help alleviate margin pressures.
However, details on how quickly this might translate into earnings growth remain scarce.
Analysts urge caution despite Berkshire’s vote of confidence
While Warren Buffett’s purchase suggests he sees long-term value in UnitedHealth, analysts remain wary.
Zacks notes that the company’s sharp earnings misses, lowered 2025 guidance, and operating cash flow collapse point to deeper structural problems.
The firm argues that the stock’s valuation premium to peers like Molina and Centene is difficult to justify given the lack of near-term visibility on a turnaround.
Until medical cost trends stabilize, regulatory threats subside, and margins recover, analysts say the risks may outweigh the potential rewards for new investors.
The post Buffett’s $1.6 bn bet lifts UnitedHealth to 16-yr high, but analysts urge caution before buying appeared first on Invezz
